ReviewClinical interventions in aging2014
Osteoporosis in men: epidemiology and treatment with denosumab.
Review in Clinical interventions in aging, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Efficacy of anti-osteoporosis treatment for men with osteoporosis: a meta-analysis.Journal of bone and mineral metabolism · 2023Pooled it
- Denosumab: A Useful Addition to the Armamentarium for the Management of Male Osteoporosis.Cureus · 2024Review
- Insights and implications of sexual dimorphism in osteoporosis.Bone research · 2024Review
- Treatment of osteoporosis using a selective androgen receptor modulator ostarine in an orchiectomized rat model.Endocrine · 2023Article
- Male osteoporosis.Archives of endocrinology and metabolism · 2022Review
- A meta-analysis of VDR polymorphisms and postmenopausal osteoporosis.Endocrine connections · 2020Article
- Bone of Contention: Helicobacter pylori and Osteoporosis-Is There an Association?Digestive diseases and sciences · 2019Review
- Zoledronic acid inhibits osteoclast differentiation and function through the regulation of NF-κB and JNK signalling pathways.International journal of molecular medicine · 2019Article
- Article
- Article
- Chemokine-like receptor 1 deficiency leads to lower bone mass in male mice.Cellular and molecular life sciences : CMLS · 2019Article
- Increased Bone Mineral Density after Abstinence in Male Patients with Alcohol Dependence.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2018Article
- DJ-1 controls bone homeostasis through the regulation of osteoclast differentiation.Nature communications · 2017Article
- A Case of Male Osteoporosis: A 37-Year-Old Man with Multiple Vertebral Compression Fractures.Case reports in endocrinology · 2017Article
- Associated Factors of Bone Mineral Density and Osteoporosis in Elderly Males.International journal of endocrinology and metabolism · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis is a major public health care concern. Although often described as a disease affecting postmenopausal women, researchers and clinicians have emphasized its prevalence in men in recent years. The National Osteoporosis Foundation has stated that up to 25% of men over the age of 50 years will experience a fracture due to osteoporosis. Men who suffer from a major fracture have higher mortality rates than women. Pharmacologic therapy options for treating osteoporosis are limited for men as compared with women, so each medication approved for use in this population represents an important clinical option. In September 2012, the US Food and Drug Administration approved a new indication for denosumab to increase bone mass in men with osteoporosis at high risk for fracture. Denosumab is a fully human monoclonal antibody and novel antiresorptive agent that works by binding receptor activator of nuclear factor kappa-β ligand (RANKL) and inhibiting the signaling cascade that causes osteoclast maturation, activity, and survival. Ultimately, denosumab suppresses bone turnover and increases bone mineral density in both trabecular and cortical bone. Approval for treating osteoporosis in men was based on data from the ADAMO trial which displayed efficacy in increasing bone mineral density at the lumbar spine, total hip, femoral neck, hip trochanter, and one-third radius. Studies indicate that denosumab is effective and safe, and has superior adherence rates and patient satisfaction. Although long-term data and further research on fracture reduction rates in men should be explored, at this time denosumab is one of several appropriate first-line treatment options for men with osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.